Evaluation of Chromogranin A Expression in Patients with Non-Neuroendocrine Tumours

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.26, Iss.12, 2006-01, pp. : 715-722

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sunitinib has demonstrated efficacy for the treatment of patients with neuroendocrine tumours

Inpharma, Vol. 1, Iss. 1648, 2008-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Investigational drugs for neuroendocrine tumours

By Granberg Dan

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 5, 2009-05 ,pp. : 601-608

Informa Healthcare

Access to resources Recommend Favorite

Nuclear medicine imaging of neuroendocrine tumours

By Al-Nahhas Adil

Clinical Medicine, Vol. 12, Iss. 4, 2012-08 ,pp. : 377-380

Royal College Of Physicians

Access to resources Recommend Favorite

Choi criteria are superior to Response Evaluation Criteria in Solid Tumours (RECIST) for evaluating GI stromal tumours in imatinib-treated patients

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Recent advances in the imaging of adrenal and neuroendocrine tumours

By Narayanan Priya Reznek Rodney

Clinical Medicine, Vol. 9, Iss. 4, 2009-08 ,pp. : 361-362

Royal College Of Physicians

Access to resources Recommend Favorite